Potential use of ivermectin for the treatment and profilaxis of SARS-CoV-2 infection: Efficacy of ivermectin for SARS-CoV-2
et al., Clin. Res. Trials, 2021, doi:10.15761/CRT.1000333, Jan 2021
Ivermectin for COVID-19
4th treatment shown to reduce risk in
August 2020, now with p < 0.00000000001 from 106 studies, recognized in 24 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,200+ studies for
200+ treatments. c19early.org
|
Review finding that there appears to be sufficient evidence to recommend ivermectin for the treatment of COVID-19, especially in the early stages of the disease.
7 meta analyses show significant improvements with ivermectin for mortality1-6,
hospitalization7,
recovery3, and
cases3.
Currently there are 106 ivermectin for COVID-19 studies, showing 47% lower mortality [34‑58%], 35% lower ventilation [17‑50%], 40% lower ICU admission [12‑58%], 34% lower hospitalization [21‑44%], and 79% fewer cases [69‑86%].
1.
Bryant et al., Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001402.
2.
Hariyanto et al., Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies, Reviews In Medical Virology, doi:10.1002/rmv.2265.
3.
Kory et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001377.
4.
Lawrie et al., Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance, Preprint, b3d2650e-e929-4448-a527-4eeb59304c7f.filesusr.com/ugd/593c4f_8cb655bd21b1448ba6cf1f4c59f0d73d.pdf.
5.
Nardelli et al., Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?, Signa Vitae, doi:10.22514/sv.2021.043.
Cobos-Campos et al., 29 Jan 2021, peer-reviewed, 9 authors.
DOI record:
{
"DOI": "10.15761/crt.1000333",
"ISSN": [
"2059-0377"
],
"URL": "http://dx.doi.org/10.15761/CRT.1000333",
"author": [
{
"affiliation": [],
"family": "Alvarado González",
"given": "Alcibey",
"sequence": "first"
}
],
"container-title": "Clinical Research and Trials",
"container-title-short": "Clin Res Trials",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
3,
24
]
],
"date-time": "2021-03-24T08:32:16Z",
"timestamp": 1616574736000
},
"deposited": {
"date-parts": [
[
2021,
3,
24
]
],
"date-time": "2021-03-24T08:32:22Z",
"timestamp": 1616574742000
},
"indexed": {
"date-parts": [
[
2023,
6,
8
]
],
"date-time": "2023-06-08T07:32:06Z",
"timestamp": 1686209526930
},
"is-referenced-by-count": 1,
"issue": "1",
"issued": {
"date-parts": [
[
2020
]
]
},
"journal-issue": {
"issue": "1",
"published-online": {
"date-parts": [
[
2020
]
]
}
},
"member": "6817",
"original-title": [],
"prefix": "10.15761",
"published": {
"date-parts": [
[
2020
]
]
},
"published-online": {
"date-parts": [
[
2020
]
]
},
"publisher": "Open Access Text Pvt, Ltd.",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.oatext.com/ige-diseases.php"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "IgE Diseases",
"type": "journal-article",
"volume": "7"
}